Want to see TRVI full AI Analyst Report?
Top Page
Trevi Therapeutics
(NASDAQ:TRVI)
Select Model
Select Model
Rating:45Neutral
Price Target:
$12.00
▼(-10.91% Downside)
Action:Reiterated
Date:10/15/26
Overall score is constrained primarily by ongoing pre-revenue losses and material cash burn, which outweigh the benefit of a very low-debt, strengthening balance sheet. Technical signals also detract meaningfully, with the stock trading below key moving averages and negative MACD, while valuation provides limited support given the negative P/E and no dividend yield data.
Positive Factors
Low leverage and stronger equity base
Very low leverage and a materially larger equity base provide financial flexibility for a clinical-stage company. This reduces balance-sheet strain and may support continued development investment, although operating performance remains dependent on future progress toward commercialization.
Negative Factors
No revenue generation
TRVI remains pre-revenue, so its business model has not yet demonstrated recurring commercial sales. This leaves future financial performance dependent on converting the development pipeline into approved, marketable products and creates substantial execution risk before revenue can support operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger equity base
Very low leverage and a materially larger equity base provide financial flexibility for a clinical-stage company. This reduces balance-sheet strain and may support continued development investment, although operating performance remains dependent on future progress toward commercialization.
Read all positive factors
Trevi Therapeutics (TRVI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.82B
Dividend YieldN/A
Average Volume (3M)2.45M
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue GrowthN/A
EPS Growth18.54%
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding142,475,850
10 Day Avg. Volume3,399,014
30 Day Avg. Volume2,446,126
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-76.54K
Enterprise Value/Ebitda-50.99
Forecast
1Y Price Target
$29.00Price Target Upside115.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.48
Revenue Forecast (FY)N/A
Trevi Therapeutics Business Overview & Revenue Model
Company Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-relea...
Trevi Therapeutics Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.Positive Updates
Strong Cash Position and Recent Financing
Ended Q1 2026 with ~$172M in cash, cash equivalents and marketable securities, plus $162M in net proceeds from an April 2026 underwritten common stock offering (total pro forma cash ~ $334M). Management states the financing extends runway into 2030 and removes financial overhang ahead of key clinical value inflection points.
Negative Updates
Competitive Uncertainty from P2X3 Readouts
Upcoming P2X3 (e.g., camlipixant) readouts could materially affect market positioning and commercial strategy. Management expects to learn from competitor placebo and trial conduct but acknowledges outcomes (positive or negative) could change competitive dynamics and go-to-market positioning.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Cash Position and Recent Financing
Ended Q1 2026 with ~$172M in cash, cash equivalents and marketable securities, plus $162M in net proceeds from an April 2026 underwritten common stock offering (total pro forma cash ~ $334M). Management states the financing extends runway into 2030 and removes financial overhang ahead of key clinical value inflection points.
Read all positive updates
Company Guidance
Management guided that Trevi finished Q1 2026 with approximately $172M in cash, cash equivalents and marketable securities (excluding ~$162M net proceeds from an April 2026 offering) and said the financing extends runway into 2030 and is expected to fund development through potential FDA approval in IPF-related chronic cough plus planned Phase IIb (and potentially Phase III) non‑IPF‑ILD and the planned RCC Phase IIb; the team finalized Phase III protocols for two IPF pivotal studies and expects to initiate the first study this quarter and the second in H2 2026, plans to submit an adaptive Phase II/III protocol for non‑IPF‑ILD to the FDA and—if agreed—initiate that study in H2 2026, and expects to initiate a RCC Phase IIb 3‑dose plus placebo trial this quarter with a sample‑size reestimation at 50% completion and an SSRE readout expected in Q4 2026 (SSRE uses an ~80% conditional‑power target with futility in the ~30–40% range); additionally, core method‑of‑treatment patents were issued in the U.S. and Europe protecting through 2039 with U.S. filings that could extend coverage to 2046.Trevi Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -34.00K | 0.00 | -147.00K | 0.00 | 0.00 | -50.00K |
| EBITDA | -51.04M | -42.68M | -47.79M | -28.58M | -27.98M | -32.71M |
| Net Income | -51.11M | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M |
Balance Sheet | ||||||
| Total Assets | 330.52M | 193.44M | 110.90M | 89.40M | 123.02M | 38.48M |
| Cash, Cash Equivalents and Short-Term Investments | 318.87M | 188.26M | 107.62M | 82.97M | 120.51M | 36.83M |
| Total Debt | 605.00K | 753.00K | 1.03M | 1.34M | 9.18M | 14.63M |
| Total Liabilities | 9.01M | 10.20M | 11.26M | 6.86M | 15.56M | 21.40M |
| Stockholders Equity | 321.51M | 183.24M | 99.64M | 82.55M | 107.46M | 17.07M |
Cash Flow | ||||||
| Free Cash Flow | -39.39M | -42.10M | -38.29M | -31.85M | -28.33M | -28.95M |
| Operating Cash Flow | -52.63M | -42.09M | -38.26M | -31.71M | -28.18M | -28.95M |
| Investing Cash Flow | -176.62M | -94.11M | -21.53M | 59.43M | -107.37M | 0.00 |
| Financing Cash Flow | 166.49M | 121.01M | 61.48M | -7.91M | 111.31M | 20.77M |
Trevi Therapeutics Technical Analysis
Negative
13.47
Price Trends
15.42
Negative
16.20
Negative
14.28
Negative
Market Momentum
-0.88
Negative
37.42
Neutral
45.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRVI, the sentiment is Negative. The current price of 13.47 is above the 20-day moving average (MA) of 13.26, below the 50-day MA of 15.42, and below the 200-day MA of 14.28, indicating a bearish trend. The MACD of -0.88 indicates Negative momentum. The RSI at 37.42 is Neutral, neither overbought nor oversold. The STOCH value of 45.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRVI.
Trevi Therapeutics Risk Analysis
Trevi Therapeutics disclosed 73 risk factors in its most recent earnings report. Trevi Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Trevi Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.79B | -26.21 | -47.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $878.30M | -2.77 | -82.68% | ― | ― | -37.48% | |
45 Neutral | $1.82B | -37.80 | -23.59% | ― | ― | 18.54% | |
45 Neutral | $560.83M | -6.57 | -61.65% | ― | -51.05% | 57.25% | |
43 Neutral | $909.10M | -1.79 | -102.97% | ― | -63.11% | 15.36% |
* Healthcare Sector Average
TRVI
Trevi Therapeutics
12.77
2.12
19.91%
PVLA
Palvella Therapeutics
126.58
55.28
77.53%
ACRS
Aclaris Therapeutics
3.81
1.55
68.58%
MLTX
MoonLake Immunotherapeutics
10.65
1.19
12.58%
ALMS
Alumis Inc.
6.81
2.20
47.72%
ALMR
Alamar Biosciences, Inc.
31.45
9.45
42.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.